Nemaline myopathy is genetically heterogeneous, meaning it can result from variants in several different genes. No specific gene list is available in the current data for this umbrella disease entity, reflecting the breadth of genetic causes. Recognized subtypes include forms with autosomal recessive and autosomal dominant inheritance, as illustrated by named subtypes such as nemaline myopathy 5B and 5C. Symptoms typically appear from birth or early infancy. Detailed genetic information relevant to a specific individual should be discussed with a clinical genetics specialist.

Diagnosis is established through clinical assessment, muscle biopsy demonstrating nemaline rods, and genetic testing. Electrophysiological studies support evaluation. A causative gene may not be identified in all individuals given the genetic heterogeneity. Pulmonary and neurological evaluations are standard components of the workup. Evaluation at a specialized neuromuscular disease center is recommended.

No FDA-approved treatments are specifically indicated for nemaline myopathy in the available data. Management focuses on supportive care including physical and occupational therapy, respiratory support (ranging from noninvasive ventilation to tracheostomy in severe cases), nutritional assistance, and orthopedic management of scoliosis and contractures. Care is provided by a multidisciplinary team. Individuals are encouraged to consult their healthcare provider to develop a personalized management plan.

Prognosis varies considerably by disease severity and subtype. Severe congenital forms carry significant challenges related to respiratory function. Milder forms may allow near-normal life expectancy with appropriate supportive care. Early identification of respiratory and orthopedic complications and access to multidisciplinary care improve outcomes. Families should discuss prognosis with their neuromuscular team.

Several clinical trials are currently underway, including natural history studies in the United Kingdom, Belgium, Spain, and the United States aimed at characterizing disease course and establishing outcome measures for future therapeutic trials. Molecular and genetic studies of congenital myopathies are ongoing. Individuals interested in research participation can search ClinicalTrials.gov or speak with their care team.